Analyst Soumit Roy from JonesTrading maintained a Buy rating on Day One Biopharmaceuticals and keeping the price target at $26.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy’s rating is based on Day One Biopharmaceuticals’ strong financial performance and promising future prospects. The company reported a significant revenue increase in the third quarter of 2025, surpassing both their own and market expectations. This growth is largely attributed to the increased confidence among physicians in prescribing Ojemda, especially after positive updates from the ASCO 2025 conference regarding the reversibility of reduced growth velocity in children.
Additionally, the adoption of Ojemda in second-line treatments has grown substantially, and new data from the Expanded Access Program (EAP) has further validated the drug’s efficacy. The upcoming 3-year update from the FIREFLY-1 trial is anticipated to provide critical insights into the long-term effects of Ojemda, potentially further boosting physician confidence. These factors collectively support the Buy rating, as they indicate a strong market position and potential for continued growth.
According to TipRanks, Roy is an analyst with an average return of -17.3% and a 26.41% success rate. Roy covers the Healthcare sector, focusing on stocks such as Cullinan Management, CervoMed, and Protara Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.